The expanding range of uses for coenzyme Q10 in many pharmaceutical and nutraceutical applications is being tapped by eminent producers. Additionally, there are certainly good chances of slowing Parkinson's disease development. Although there are few preventative medications now available, significant stage II clinical trials have shown success rates in individuals who took coenzyme Q10 at doses of 300, 600, or 1200 mg/day.
Key Takeaways from the Market Study
- Pharmaceutical uses of coenzyme Q10 continue to dominate, growing at a 7% CAGR.
- North America is anticipated to be the most opportunistic market, acquiring 45% revenue by 2031 from ubiquinone and ubiquinol coenzyme Q10 varieties.
- Asia will provide more than one-fourth of the world's coenzyme industry's income.
Prominent players operating in the global coenzyme Q10 market include Kaneka Corporation, Xiamen Kingdomway Group, Nisshin Seifun Group, Zhejiang Medicine Co. Ltd, and Kyowa Hakko U.S.A. Inc., among others.
- Skin care companies, such as Beiersdorf, have recognized the potential of coenzyme Q10 in preventing premature ageing and energizing the skin, and is offering new skin care products with CoQ10 content that claims to protect the skin from UV/UVB rays.
More Valuable Insights
Fact.MR, in its new offering, presents an unbiased analysis of the global coenzyme Q10 market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031.
The study indulges essential insights on the market on the basis of product type (ubiquinone and ubiquinol), production method (microbial fermentation and chemical synthesis) and end use industry (pharmaceuticals, nutraceuticals, cosmetics and others) across seven major regions (North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa).